Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001869 · ClinicalTrials.gov registry record

Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)

A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
400
Enrollment target

NCT00001869 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 400 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001869 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
400 participants
Enrollment target

Study Summary

Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. In order to better study this disease, the National Heart, Lung, and Blood Institute (NHLBI) has developed a registry to keep an official record of patients diagnosed with LAM. This research project will collect data from 6 health care centers as well as outside physicians. Researchers hope to provide valuable information about the rate of lung destruction and quality of life in patients with LAM. Patients participating in this study will be followed for 5 years. Tissue collected from these patients may contribute to the development of future studies on the disease processes of LAM.

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 1998-12
Est. Completion 2003-04

What the Registry Record Tells You About NCT00001869

The ClinicalTrials.gov registry entry for NCT00001869 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00001869 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001869 about?

NCT00001869 is a clinical study titled "Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)". Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. In order to better study this disease, the National Heart, Lung, and Blood Institute (NHLBI...

What is the current status of trial NCT00001869?

This trial is currently completed. The enrollment target is 400 participants. The study started on 1998-12. Estimated completion is 2003-04.

Who is sponsoring clinical trial NCT00001869?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.